Peter Goldschmidt is new CEO of STADA, group which includes Hemofarm

Goldschmidt (53) is an experienced generics manager and OTC expert who was most recently President of SANDOZ US, the global generics division of Novartis, and Head of North America. Goldschmidt will be focused on continuing STADA’s growth strategy that Albrecht successfully reinvigorated and advanced in 2017.

– Peter Goldschmidt is the right man that STADA needs in the driving seat going forward,” said Chairman of the Supervisory Board Günter von Au.

– With his three decades of experience, I am confident he will ensure that STADA successfully retains its strong competitive position,” added von Au.

He describes Goldschmidt as a “strongteam player who has a long-term focus on building the portfolio and an excellent network in the pharmaceutical world”.

Goldschmidt came to STADA from the Novartis Group, where he held various senior management positions in Europe, Asia, and the US over the past 28 years. Previously, Peter Goldschmidt was also the Global Executive Member for Central and Eastern Europe for Sandoz, where he led Sandoz to a market leading position in generics and strongly grew its OTC business.

– Naturally, I have known STADA as akey player in the industry for many years, and I see enormous potential for the Group. Together with all employees we will strive to fully capitalise on the opportunities for growth, announced the new CEO.

Goldschmidt intends to use the next 100 days to intensively get to know the Group, its partners, and its customers, and will then discuss his strategic priorities with his team.

– I am in complete alignment with ou rmajority owners, Cinven and Bain Capital, on their strategy for building a company with long-term growth potential. Using the financial resources at their disposal, our focus remains on continuing to market a competitive portfolio and working closely withour global network of strategic development and production partners,Goldschmidt said.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. STADA also includes Serbian pharmaceutical company Hemofarm from Vrsac .

In financial year 2017, STADA achievedadjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 433.9 million and adjusted net income of EUR 195.6 million. Asof December 31, 2017, STADA employed 10,176 people worldwide.